Key Highlights

  • ImmunityBio (NASDAQ:IBRX) closed at USD 8.29 on September 8, 2026 and USD 9.75 on October 7, and a published screen shows a one-month gain of 19.31% at USD 9.54 on October 8.
  • The stock rose 10.9% to USD 10.29 on October 2 on 31.3 million shares, and hit USD 10.38 on October 5, but no company announcement was found for either session.
  • Founder Patrick Soon-Shiong will join a Piper Sandler Virtual Oncology Symposium fireside chat on October 16, 2026 from 1:00 p.m. to 1:25 p.m. ET, according to an October 8 company release.
  • ImmunityBio (NASDAQ:IBRX) is valued near USD 10.1 billion, so it is not a penny cap, and its 52-week range of USD 1.95 to USD 12.43 shows it has climbed far in a year.

A Momentum Run Without News

ImmunityBio closed at USD 7.72 on September 10, 2026, then climbed to USD 9.29 on September 22 on 21.1 million shares and USD 9.44 on September 30 on 27.3 million. On October 2 it rose 10.9% to USD 10.29 on 31.3 million shares, a heavy reading. Short headlines on October 1 to 3 flagged intraday gains of about 11% to 12% with no reason attached. The only company items in the window were an August 10 appointment of Dr. Jim Yong Kim as vice chairman and the October 8 announcement of the Piper Sandler appearance. Without a filing, the move looks like momentum in a heavily traded biotech.

Business Backdrop

ImmunityBio sells Anktiva, an immunotherapy for bladder cancer, which a March 2026 release said had reached Macau as the thirty-fourth country where it is commercially available. In that month the company secured USD 75 million of non-dilutive financing from Oberland Capital, and affiliate Nant Capital converted USD 25 million of Debt into about 4.6 million shares, reducing a USD 505 million Promissory Note owed to Nant Capital. On September 14, 2026 Soon-Shiong's Nant Capital led a PIPE in PDS Biotech and he joined its board, an item that appeared on the ImmunityBio news feed because of Soon-Shiong's role. The debt conversion reduced Leverage a little, but the note remains a large claim on the business.

Risks and What to Watch

The stock is up roughly fourfold from its 52-week low of USD 1.95, and put Volume was heavy and bearish around September 10, a headline noted. A large debt load to an affiliate, commercial launch costs and the need to grow Anktiva sales remain key risks. Heavy volume of 11.8 million to 31.3 million shares a day shows how actively it trades, which can magnify reversals. Watch the October 16 symposium, the third quarter report estimated for November 3, 2026 and any new country approvals or label updates. Related-party financing from an affiliate of the chairman can draw investor scrutiny. Debt service and any new financing would also matter.

Where Things Stand

ImmunityBio (NASDAQ:IBRX) rose about 19% in a month without a verified company catalyst, so the move should be read as momentum in a heavily traded biotech, now valued near USD 10 billion. Anktiva commercial progress and the October 16 symposium are the nearest items. Debt, launch costs and a nearly fourfold rise from the 52-week low add Reversal risk. Watch the November 3 estimated report. Watch whether Anktiva sales growth supports a USD 10 billion value.